Neurocrine Biosciences (NBIX) revenue breakdown
By product, Net product sales is the largest at 99% of fiscal 2025 revenue, growing 49% a year over 8 years.
Revenue by product
Fiscal years, as Neurocrine Biosciences reports them in its 10-K filings; fiscal 2025 total $2.9B.
| Products | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| Net product sales | $117M | $410M | $753M | $994M | $1.1B | $1.4B | $1.9B | $2.3B | $2.8B | 99% |
| Collaboration revenues | $45M | $42M | $35M | $52M | $43M | $48M | $26M | $25M | $27M | 1% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for NBIX.
Open NBIX in InvestinglyQuestions
Where does Neurocrine Biosciences make its money?
In fiscal 2025, by product: Net product sales $2.8B, Collaboration revenues $27M.
From Neurocrine Biosciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.